This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Advertisement


Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   May. 3, 2013


Advertisement

Advertisement

Advertisement
 

Advertisement

Groundbreaking surgery for girl born without windpipe
The New York Times
Using plastic fibers and human cells, doctors have built and implanted a windpipe in a 2 ½-year-old girl — the youngest person ever to receive a bioengineered organ. The surgery, which took place on April 9 at Children's Hospital of Illinois is only the sixth of its kind and the first to be performed in the United States. It was approved by the Food and Drug Administration under rules that allow experimental procedures when otherwise the patient has little hope of survival.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Advertisement


SOCIETY NEWS


Join AST's 2nd online journal club on May 6!
Join the Thoracic and Critical Care COP and author Dr. Ramsey Hachem, at 3 p.m. ET on Monday, May 6, for a virtual discussion of "Antibodies to K-α 1 Tubulin and Collagen V Are Associated with Chronic Rejection after Lung Transplantation" from the August 2012 AJT. Pre-register here to secure your place and receive reminder emails leading up to the journal club. For more information on AST's online journal club, click here.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


AST offers free webinars live and on demand
AST's Timely Topics in Transplantation webinar series is available free to members 24/7 online. Newly-added webinars include "DSA: New Concerns and New Therapies," "New Strategies in Hepatitis Management," and "Meeting the Challenges of Resistance." AST's Business of Transplantation webinar series consists of live monthly webinars available in archive format shortly after the air date. To see the May and June broadcast dates, or view archived broadcasts, click here.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


AST Board of Directors online elections now open
Eligible AST members are encouraged to cast their votes for the AST Board of Directors, as well as various bylaw revisions. The voting site will prompt you to login to the AST website where you will find more detailed information. Usernames and passwords were sent to eligible members earlier this week. Election results will be announced at the AST Town Hall meeting at ATC on Monday, May 20, at 5:45 p.m. in Room 3 A/B of the Washington State Convention Center. Email Nicole Poponi, AST Director of Membership, with questions.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement
FEATURED ADVERTISER
 
Innovation in Surgical Retraction

Thompson Surgical Instruments, Inc. is the market leader in surgical retraction and the manufacturer of the original table mounted retractor. For more information, visit our website at thompsonsurgical.com or email us at info@thompsonsurgical.com.
 


AST Institutional Support Program
  • Are you interested in receiving recognition and increased exposure for your transplant center?
  • Does your center support the future of transplantation and value the educational, networking, and research opportunities that the American Society of Transplantation (AST) provides to its members?
  • Does your center support AST's lobbying of the U.S. Congress and Federal Agencies to secure a more transplant provider friendly environment for patients and physicians?
If the answer to these questions is YES, please consider having your center participate in AST's Institutional Support Program. With a charitable contribution of $3,000, your center will receive valuable benefits. For more information and to make a contribution, click here. All donations are tax-deductible.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


AST @ ATC


Attention job seekers: Participate in AST's Career Connections at ATC
Are you currently looking for a new position in the field of transplantation? Will you be attending the ATC in Seattle? Then we encourage you to browse AST's Career Center for open jobs and participate in the ATC Career Connections Event! All job postings with the ATC logo next to them indicate that the employer will also be attending ATC. These employers are looking to potentially interview candidates they are interested in while both parties are at the meeting. Should an employer wish to meet with you face-to-face, they will coordinate a mutually convenient time, and AST will provide a space for the interview to be conducted. Click here to learn more about this opportunity. If you have any questions, please contact the AST National Office at info@myAST.org.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement


AST town hall meeting: Many voices, one goal
AST members are invited to attend a town hall meeting at ATC on Monday, May 20 at 5:45 p.m. in room 2 A/B at the Washington State Convention Center. The town hall will provide a forum for open discussion between the membership and the leadership about key issues impacting the society and field of transplantation, and how the society is positioned to address those key issues. In addition, we'll announce the Board of Director election results, recognize and honor AST volunteer leadership, and award the 2013 research grants. RSVP for the Town Hall/Excellence in Transplantation Reception here.

If you are not already an AST member and are interested in learning more, click here to complete an online membership application. The town hall meeting is supported in part with funding from Genentech, Sanofi and Association Headquarters.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Stop in at AST events!
AST is hosting a variety of meetings and events at ATC, and you're invited! Click here for a list of events open to both members and non-members. Contact Jason Polinsky with questions.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Featured Advertisers


Advertisement
Astellas Pharma US, Inc.

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us
Advertisement
New LIFECODES SSO Typing Kits

LIFECODES is introducing its new HLA-SSO kits. The new kit includes a validated, high-performance enzyme for improved reliability and performance with the continued ease of no centrifugation or wash steps; providing accurate, clear and easy to interpret results.
Advertisement
Genzyme


Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. MORE


TRANSPLANT NEWS


Pediatric post-transplant metabolic syndrome: New clouds on the horizon
Pediatric Transplantation (subscription required)
Liver transplantation (LT) is a standard treatment for children with end-stage liver disease, standing at more than 90 percent survival rate after one year, and more than 70 percent survival rate after five years. The majority of transplanted children enjoy an excellent quality of life but complications can occur in the long term, and can develop subclinically in otherwise well children; there are various underestimated nutritional and metabolic aspects, including the so-called post-transplant metabolic syndrome (PTMS).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Everolimus-based immunosuppression post-liver transplant as effective as tacrolimus with better renal function
Healio
Liver transplant recipients who received everolimus-based immunosuppression with reduced tacrolimus experienced similar results to those treated with standard tacrolimus, while maintaining better renal function, in a study presented at the International Liver Congress in Amsterdam.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineruin inhibitor-free regimen
Clinical Transplantation (subscription required)
Scarce data exist regarding the incidence of donor-specific antibodies (DSAs) in kidney transplant patients receiving everolimus-based immunosuppression without calcineurin inhibitors (CNIs). The aim of this retrospective case-control study was to compare the incidence of de novo DSAs in patients converted to an everolimus-based regimen without CNIs with that seen in patients maintained on CNIs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Transmission of Strongyloides stercoralis through transplantation of solid organs (Centers for Disease Control and Prevention)
Reciprocal interaction between intestinal microbiota and mucosal lymphocyte in cynomolgus monkeys after alemtuzumab treatment (American Journal of Transplantation)
Outcomes and predictive factors of pediatric kidney transplants: An analysis of the Thai Transplant Registry (Pediatric Transplantation)

Don't be left behind. Click here to see what else you missed.


Suppression of NF-kappaB p65 expression attenuates delayed xenograft rejection
Xenotransplantation
Delayed xenograft rejection (DXR) involves type II vascular endothelial cell (VEC) activation including upregulation of pro-inflammatory genes, which contributes to infiltration into the graft and a complex process of cytokine production. Approaches to prevent DXR have shown limited success. In this study, researchers modified heart donors using siRNA in an attempt to attenuate DXR and to improve xenograft survival in the mouse-to-rat heterotopic heart transplant model.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers


Advertisement
Put Science on Your Side

Drug Monitoring Platforms since 1981.

Learn More
Advertisement
Exclusively Focused Transplant Pharmacy Therapeutics
Transplant IV Biologics and Oral Immunosuppressives specializing in Desensitization and AMR Treatment and Prevention. MORE


Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis
Journal of the American Society of Nephrology
The molecular mechanisms that maintain podocytes and consequently, the integrity of the glomerular filtration barrier are incompletely understood. Here, researchers show that the class III phosphoinositide 3-kinase vacuolar protein sorting 34 (Vps34) plays a central role in modulating endocytic pathways, maintaining podocyte homeostasis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Cystathionine γ-Lyase protects against renal ischemia/reperfusion by modulating oxidative stress
Journal of the American Society of Nephrology (login required)
Hydrogen sulfide (H2S) is an endogenous gasotransmitter with physiologic functions similar to nitric oxide and carbon monoxide. Exogenous treatment with H2S can induce a reversible hypometabolic state, which can protect organs from ischemia/reperfusion injury, but whether cystathionine γ-lyase (CSE), which produces endogenous H2S, has similar protective effects is unknown. In a recent study, human renal tissue revealed abundant expression of CSE, localized to glomeruli and the tubulointerstitium.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation
Clinical Transplantation (subscription required)
Liver transplantation is the optimal treatment for patients with hepatocellular carcinoma (HCC) and cirrhosis. This study was conducted to determine the impact of pre-transplant locoregional therapy (LRT) on HCC and our institution's experience with expansion to United Network of Organ Sharing Region 4 T3 (R4T3) criteria.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Severe lung injury, biopsy in children post-hematopoietic stem cell transplantation: Differences between allogeneic and autologous transplantation
Pediatric Transplantation (subscription required)
A study was conducted recently to review outcome of children post-allogeneic (allo) and autologous (auto) SCT with severe lung injury who had lung biopsy and to determine whether the diagnoses provided by lung biopsy had an impact on outcome. A retrospective study was carried out from January 2000 to June 2010. The most common result of lung biopsy was non-infectious inflammation and recurrent disease in allo- and autorecipients, respectively. In a multivariate analysis, survival of allorecipients who had management change was inferior (p = 0.002; HR: 3.12). These patients were extremely sick, and management change was the last attempt to stabilize their respiratory status.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
April 26, 2013
April 19, 2013
April 12, 2013
April 4, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063